来源：环球网 会议开幕式由首都医科大学宣武医院郑亚民教授主持，雄安宣武医院院长李嘉教授、中国研究型医院学 会刘希华副会长致辞。李嘉教授介绍了雄安新区建设的显著成就，强调本次会议作为新区新年首场高水 平学术盛会，实现了区域性与国家级平台深度联动，将为学科发展注入新活力。刘希华副会长阐述了研 究型医院 "医学创新、难病诊治、创新转化" 的核心要义，高度肯定了老年外科专委会的成果，鼓励专 家坚持临床与科研并举。 《中华外科杂志》主编李静教授、首都医科大学宣武医院刘东斌教授、首都医科大学附属北京天坛医院 程石教授以及北京协和医院李秉璐教授共同主持了《共识》发布会。 《共识》牵头专家首都医科大学宣武医院李非教授表示，随着人口老龄化加深，老年胆道结石诊疗已成 为涉及多学科评估、全程化管理与人文关怀的系统性工程。《共识》汇聚全国26家中心、26位专家智 慧，历时一年多筹备修订，基于3000余例老年病例回顾性分析、多次多学科论证及循证医学考量，在手 术适应症、围术期评估等方面形成清晰指引。 上海交通大学医学院附属新华医院全志伟教授感谢全国专家参与编写，指出《共识》解决了"手术还是 观察"的临床决策痛点，感谢上海和黄药业及《中 ...

Group 1: Conference Overview - The 18th Health Industry (International) Ecological Conference, known as the 2025 Xipu Conference, was held in Boao, Hainan, from August 16 to 21, focusing on the theme "Rapid Transformation, Crossing New Cycles - Reconstruction of Growth Drivers and Evolution of Industrial Ecology" [1] - The conference aims to explore how the health industry can achieve a leap from "single-point innovation" to "comprehensive transformation" amid pressures on traditional growth models and the reshaping of industry patterns by emerging technologies [1] Group 2: Product Recognition - The "2025 Health China Brand List" was announced during the conference, with Shanghai Huan Pharmaceutical's flagship product, "Shangyao Brand" Musk Heart Pill, receiving the highest honor, the "Xipu Gold Award" [1][10] Group 3: Product Development and Research - The Musk Heart Pill is derived from the Song Dynasty's "Suhexiang Pill" and has been modernized through continuous optimization by a team from Fudan University [3] - The formulation includes artificial musk, ginseng extract, artificial beef bile, cinnamon, suhexiang, toad venom, and borneol, demonstrating clear pharmacological effects and mechanisms [3] - The product has established a modern research system based on evidence-based medicine, accumulating substantial scientific evidence over the years [3][10] Group 4: Clinical Research Findings - The MUST study, a large-scale evidence-based research project, involved 2,673 stable coronary artery disease (CAD) patients across 97 hospitals, showing that the Musk Heart Pill significantly improves clinical outcomes when combined with conventional Western medicine [4] - The MUST-D subgroup analysis focused on CAD patients with diabetes, revealing a 45.8% reduction in major adverse cardiovascular events (MACE) compared to the placebo group [5] - The MUST-E study highlighted the economic advantages of the Musk Heart Pill, indicating lower long-term costs and higher health outcomes compared to placebo [6] Group 5: Gender and Weight-Specific Analyses - The MUST-F subgroup analysis indicated that the Musk Heart Pill significantly reduces MACE rates in female CAD patients, with a 0.5% occurrence compared to 2.6% in the placebo group [7] - The MUST-W subgroup analysis found a 75.4% reduction in MACE rates for CAD patients weighing less than 65 kg, suggesting the need for personalized treatment for those weighing 65 kg or more [8] Group 6: Broader Impact and Future Research - The LESS study evaluated the Musk Heart Pill's efficacy in patients with angina and non-obstructive coronary artery disease (ANOCA), showing significant improvements in angina symptoms and quality of life [9] - The ongoing research and recognition of the Musk Heart Pill contribute to its growing global influence, setting a precedent for the modernization and internationalization of traditional Chinese medicine [9][10]